Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®
Sponsor: Pfizer
Summary
To compare efficacy and safety of Exubera® vs Lantus® in patients with type 2 diabetes mellitus.
Official title: A Six Month, Open-Label Outpatient, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera®) On Glycemic Control Compared To Insulin Glargine (Lantus®) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents
Key Details
Gender
All
Age Range
30 Years - Any
Study Type
INTERVENTIONAL
Enrollment
261
Start Date
2006-12
Completion Date
2008-08
Last Updated
2026-08-11
Healthy Volunteers
No
Conditions
Interventions
Insulin Glargine (Lantus®)
Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.
Inhaled Human Insulin (Exubera®)
Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
Locations (62)
Pfizer Investigational Site
Bornem, Belgium
Pfizer Investigational Site
Brussels, Belgium
Pfizer Investigational Site
Genk, Belgium
Pfizer Investigational Site
Liège, Belgium
Pfizer Investigational Site
Kuopio, Finland
Pfizer Investigational Site
Lahti, Finland
Pfizer Investigational Site
Oulu, Finland
Pfizer Investigational Site
Besançon, France
Pfizer Investigational Site
Corbeil-Essonnes, France
Pfizer Investigational Site
La Rochelle, France
Pfizer Investigational Site
Marseille, France
Pfizer Investigational Site
Paris, France
Pfizer Investigational Site
Valenciennes, France
Pfizer Investigational Site
Altenburg, Germany
Pfizer Investigational Site
Eisenach, Germany
Pfizer Investigational Site
Hamburg, Germany
Pfizer Investigational Site
Hohenmölsen, Germany
Pfizer Investigational Site
Leipzig, Germany
Pfizer Investigational Site
Neuss, Germany
Pfizer Investigational Site
Riesa, Germany
Pfizer Investigational Site
Wangen / Allgaeu, Germany
Pfizer Investigational Site
's-Hertogenbosch, Netherlands
Pfizer Investigational Site
Eindhoven, Netherlands
Pfizer Investigational Site
Nijmegen, Netherlands
Pfizer Investigational Site
The Hague, Netherlands
Pfizer Investigational Site
Venlo, Netherlands
Pfizer Investigational Site
Hønefoss, Buskerud, Norway
Pfizer Investigational Site
Bergen, Norway
Pfizer Investigational Site
Jessheim, Norway
Pfizer Investigational Site
Lysaker, Norway
Pfizer Investigational Site
Skedsmokorset, Norway
Pfizer Investigational Site
Lodz, Poland
Pfizer Investigational Site
Lodz, Poland
Pfizer Investigational Site
Lublin, Poland
Pfizer Investigational Site
Warsaw, Poland
Pfizer Investigational Site
Łask, Poland
Pfizer Investigational Site
Palma de Mallorca, Balearic Islands, Spain
Pfizer Investigational Site
Inca, Mallorca, Spain
Pfizer Investigational Site
San Cristóbal de La Laguna, Santa CRUZ DE Tenerife, Spain
Pfizer Investigational Site
Alzira, Valencia, Spain
Pfizer Investigational Site
A Coruña, Spain
Pfizer Investigational Site
Huelva, Spain
Pfizer Investigational Site
Málaga, Spain
Pfizer Investigational Site
Valencia, Spain
Pfizer Investigational Site
Borås, Sweden
Pfizer Investigational Site
Eksjö, Sweden
Pfizer Investigational Site
Gothenburg, Sweden
Pfizer Investigational Site
Gothenburg, Sweden
Pfizer Investigational Site
Härnösand, Sweden
Pfizer Investigational Site
Helsingborg, Sweden
Pfizer Investigational Site
Järfälla, Sweden
Pfizer Investigational Site
Kristianstad, Sweden
Pfizer Investigational Site
Linköping, Sweden
Pfizer Investigational Site
Luleå, Sweden
Pfizer Investigational Site
Malmö, Sweden
Pfizer Investigational Site
Motala, Sweden
Pfizer Investigational Site
Stockholm, Sweden
Pfizer Investigational Site
Uddevalla, Sweden
Pfizer Investigational Site
Umeå, Sweden
Pfizer Investigational Site
Vaxjo, Sweden
Pfizer Investigational Site
Bruderholz, Switzerland
Pfizer Investigational Site
Sankt Gallen, Switzerland